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Iritroduction 
It is difficult to assess changes in the function of small 
airways using conventional measures of pulmonary func- 
tion since these measurements are relatively insensitive, 
variable and/or physiologically non-specific. Recent ad- 
vances in high-resolution computed tomography (HRCT) 
imaging have made it possible to obtain non-invasive 
reproducible measurements of structure-function relation- 
ships within the lung. This technique has great potential for 
diagnosing changes in small airway function and in 
assessing response to drug treatment. 
This article will outline the role of HRCT in elucidating 
the effects of HFA-BDP within the small airways. The data 
presented herein have been adapted from References 1-3. 
High-resolution computed 
tomography to assess small 
airways function 
High-resolution computed tomography (HRCT) is a non- 
invasive imaging technique that can be used to assess 
pulmonary structure-function relationships (4-6). It allows 
direct radiographic evaluation of luminal calibre and wall 
thickness of macroscopic airways >2mm in diameter (7), 
although direct measurement of changes in the calibre of 
the small airways (<2mm in diameter) is not yet possible. 
However, HRCT can be used to indirectly assess the small 
airways by measuring the regional air trapping that results 
from small airways narrowing and the hyperreactivity of 
the small airways to methacholine (8.9). HRCT is also more 
sensitive than spirometry (8,lO) in providing an accurate 
and reproducible assessment of small airways changes in 
mild asthma. 
Regional air trapping can be assessed by analysis of lung 
attenuation curves (LAC) which represent the frequency 
distribution of lung attenuation units within axial sections 
in a region of interest; a shift to the left (to lower 
attenuation) in the LAC at a given standardized lung 
volume (usually residual volume) reflects an increase in air 
trapping, whereas a shift to the right (to higher attenuation) 
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reflects improvement in air trapping that may be attributed 
to therapeutic efficacy (8). 
Thus, functional HRCT provides reproducible measure- 
ments of cross-sectional area of macroscopic airways, as 
well as regional attenuation characteristics reflecting the 
patency of peripheral airways. This imaging technique is 
thought to be more sensitive than pulmonary function tests 
in the early stages of chronic airways disease and has 
considerable potential for use in the diagnosis and long- 
itudinal evaluation of patients. 
Inhaled corticosteroids and the small 
airways 
As prophylactic agents, corticosteroids have been the 
cornerstone of asthma treatment. Inhaled corticosteroids 
(ICS) have now become established as first-line treatment 
for patients with persistent asthma (I 1,12). 
It is clear that anti-inflammatory treatment needs to be 
directed to both large and small airways to achieve maximal 
suppression of inflammation (13). However, only about 
10% of the steroid dose generated from chlorofluorocarbon 
(CFC)-based metered-dose inhalers reaches the lower 
respiratory tract with the greater part of the medication 
being deposited in the large airways (14). 
The most widely used ICS preparations in Europe are 
beclomethasone dipropionate (BDP), budesonide and 
fluticasone propionate, with BDP being the first and still 
the most commonly prescribed ICS. BDP reformulated 
with the alternative propellant, hydrofluoroalkane (HFA)- 
134a, results in a solution pFeparation that delivers an 
aerosol with a much smaller mean particle size (MMAD 
0-8-1.2/1m) than that of the suspension aerosols generated 
by conventional chlorofluorocarbon 1 l/l2 (CFC)-based 
metered dose inhalers of BDP (MMAD 3.5-4pm). The 
availability of an extrafine corticosteroid aerosol raises the 
possibility of more effective delivery of inhaled anti- 
inflammatory medication to the lung periphery in asthmatic 
patients and thus more effective suppression of inflamma- 
tion and improved function of the small airways in asthma. 
HFA-BDP and the small airways 
HRCT was used to address the hypothesis that, compared 
to a CFC-based inhaled corticosteroid [beclomethasone 
diproprionate (BDP)] (BecloventTM), 3 M HFA-BDP 
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(QVARTM, 3M Pharmaceuticals, St Paul, MN, U.S.A.), 
administered in the same low dose (SOpgpuff- ex-v&e, 
two puffs twice daily), would lead to greater improvement 
in small airways patency in patients with mild-to-moderate 
persistent asthma (FEV,>60% predicted; 
PCz&4mgml-‘) after a one month course of treatment. 
Changes in small airways patency were assessed indirectly 
using a validated thoracic HRCT technique for quantitat- 
ing changes in regional hyperinflation (8, IO). 
Variations in lung attenuation as an indirect measure of 
air trapping were characterized in two ways from the LAC: 
median lung attenuation and the lowest 10th percentile of 
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FIG. 1. Axial lung section divided into three area- 
equivalent gravitational zones (anterior or non- 
dependent, middle, and posterior or dependent), 
corresponding to West’s three physiologic zones (16). 
TABLE 1. Median lung attenuation at RV, pre-methacho- 
line, mid lung zone, RLL 
Baseline Post-treatment Change 
CFC group -695+72* -692+61 3 
(n=15) 
HFA group -674k89 -635+77 39 
(n = 16) 
*Hounsfield units (HU); mean + SD 
Source: Ref. 1. 
the frequency distribution (15). Lung attenuation was 
assessed on these parameters for the regions of interest in 
the right upper and lower lobes at the different measure- 
ment times. Automated routines divided axial right lung 
sections into three area-equivalent gravitational zones: 
anterior (non-dependent), middle and posterior (depen- 
dent), intended to correspond roughly to West’s three 
physiologic zones (16) (Fig. 1). At any axial level, whole 
lung as well as regional (gravitational zone) measurements 
were obtained. 
The average median pre-methacholine lung attentuation 
increased by 39 units in the HFA group between the two 
visits (indicating less regional air-trapping) but remained 
essentially unchanged in the CFC group (Table I). 
The average (-I 1 SD) median values of lung attenuation 
determined from LACs from matched pairs of both pmand 
post-tne~hacholine images obtained in the mid zone of the 
region of interest in the right lower lobe at the baseline and 
post-treatment visits are shown in (Table 2). 
At the baseline visit, the reduction in lung attenuation 
after methacholine (indicating worsening regional air- 
trapping in response to methacholine) is similar for the 
HFA and CFC groups (-29 vs. -26, respectively; 
P=O*90). In contrast, at the post-treatment visit, the 
magnitude of the decrease in lung attenuation in response 
to methacholine is reduced in the HFA group compared to 
the baseline response in the same subjects (- 17 vs. - 29), 
while the magnitude of the decrease in lung attenuation 
following methacholine compared to the baseline response 
is augmented in the CFC group. The difference in the effects 
of the two treatments (HFA vs. CFC) on response to 
methacholine is statistically significant (P = 0*04), implying 
a relatively more favourable effect on regional hyperreac- 
tivity after treatment with HFA- than with CFC-BDP. 
Moreover, the lung attenuation response to methacholine 
improved (i.e. lung attenuation decreased less, implying less 
increase in regional air-trapping induced by methacholine) 
significantly more often following treatment with HFA- 
BDP than CFC-BDP. 
In summary, this study demonstrates a greater efficacy of 
HFA-BDP compared to CFC-BDP in reducing regional 
air-trapping, as assessed by changes in the regional 
distribution of lung attenuation. In addition, greater 
efficacy of HFA-BDP is also shown in reducing regional 
airways hyperreactivity, as determined by changes in 
regional air-trapping after bronchoprovocation with 
TABLE 2. Median lung attenuation at RV, mid lung zone, RLL 
Baseline 
Pre-MCT Post-MCT A 
CFC (n = 9) -690&93* -716k84 -26 
HFA(n = 11) -692k68 -721+70 -29 
*HU; +P<O*04; difference from AA for CFC group. 
Source: Ref. I. 
Pre-MCT 
-680575 
-646f57 
Post-treatment 
Post- MCT A AA 
-740f80 -60 -34 
-663+80 -17 12*+ 
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methacholine, again assessed by analysing changes in the 
distribution of lung attenuation. These differences between 
the effects of the two formulations of BDP on regional air- 
trapping and regional hyperreactivity are consistent with 
the greater penetration of the smaller airways by the extra- 
fine HFA, compared to the larger particle size CFC, 
corticosteroid aerosol previously demonstrated by radio- 
labelled aerosol deposition studies (17). 
Conclusion 
In conclusion, functional imaging provides a sensitive new 
tool for assessing the long-term effect of corticosteroid 
aerosols on small airways function. Using this new 
assessment tool it has been shown that the extrafine 
HFA-BDP aerosol appears to have greater efficacy than 
the same dose of the larger particle size CFC-BDP aerosol 
on small airways function, most likely due to the more 
effective delivery of the extrafine corticosteroid aerosol to 
the lung periphery. Additional studies are needed in larger 
numbers of patients with asthma of varying severity over 
longer periods of time to assess further the impact of 
targeting the small airways for treatment with anti- 
inflammatory agents on lung function and other clinical 
outcomes. 
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